Cancer Immunology, Immunotherapy

, Volume 57, Issue 5, pp 663–675

Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

  • Hovav Nechushtan
  • Dien Pham
  • Yu Zhang
  • Daniel Morgensztern
  • Kyung H. Yi
  • Seung-Uon Shin
  • Howard J. Federoff
  • William J. Bowers
  • Khaled A. Tolba
  • Joseph D. Rosenblatt
Original Article

Abstract

Treatment of cancer with cytotoxic agents may induce lymphopenia. Adoptively transferred T cells have been reported to display enhanced anti-tumor efficacy in the lymphopenic setting. We reasoned that the anti-tumor effects of adoptively transferred cells in the lymphopenic host could be further augmented through local provision of an innate stimulus in the tumor bed. Utilizing a model in which mice were irradiated to induce lymphopenia, with limited shielding to allow tumor growth, we demonstrate that “triple” therapy consisting of radiation-induced lymphopenia, adoptive transfer of naïve CD8+ T cells, and intra-tumoral HSV amplicon injection resulted in reduced tumor growth compared to the combination of any two of the aforementioned interventions. To gain insight into the mechanism underlying this effect we studied the effects of HSV amplicon transduction into tumors on cytokine expression and on anti-tumor specific T cells. HSV amplicon transduction specifically induced several cytokine mRNAs including IFN-γ, and IP-10. Adoptively transferred transgenic OT-1 T cells directed against Ovalbumin were more effective against Ovalbumin-expressing tumors when combined with intra-tumoral HSV amplicon injections in the lymphopenic host. Following intra-tumoral HSV-amplicon injections, anti-tumor T cells secreted higher levels of interferon-γ in response to in-vitro re-stimulation with tumor cells, implying that HSV amplicon injection provided a strong signal for T cell activation. Combining adoptive transfer of naïve T cells in the lymphopenic setting with local T cell stimulation may facilitate expansion and activation of anti-tumor T cell populations in vivo, resulting in enhanced anti-tumor responses without the need to resort to prolonged in vitro T cell culture and/or manipulation.

References

  1. 1.
    Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M (2003) Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171:3941–3946PubMedGoogle Scholar
  2. 2.
    Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ (2001) Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167:4878–4886PubMedGoogle Scholar
  3. 3.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854PubMedCrossRefGoogle Scholar
  4. 4.
    Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA et al (2005) Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357PubMedCrossRefGoogle Scholar
  5. 5.
    Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675PubMedCrossRefGoogle Scholar
  6. 6.
    Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352PubMedCrossRefGoogle Scholar
  7. 7.
    Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627–630PubMedCrossRefGoogle Scholar
  8. 8.
    Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH et al (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117:574–586PubMedCrossRefGoogle Scholar
  9. 9.
    Goldrath AW, Bogatzki LY, Bevan MJ (2000) Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192:557–564PubMedCrossRefGoogle Scholar
  10. 10.
    Ge Q, Hu H, Eisen HN, Chen J (2002) Naive to memory T-cell differentiation during homeostasis-driven proliferation. Microbes Infect 4:555–558PubMedCrossRefGoogle Scholar
  11. 11.
    Goldrath AW, Luckey CJ, Park R, Benoist C, Mathis D (2004) The molecular program induced in T cells undergoing homeostatic proliferation. Proc Natl Acad Sci USA 101:16885–16890PubMedCrossRefGoogle Scholar
  12. 12.
    Tanchot C, Le Campion A, Martin B, Leaument S, Dautigny N, Lucas B (2002) Conversion of naive T cells to a memory-like phenotype in lymphopenic hosts is not related to a homeostatic mechanism that fills the peripheral naive T cell pool. J Immunol 168:5042–5046PubMedGoogle Scholar
  13. 13.
    Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE (2003) Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63:8466–8475PubMedGoogle Scholar
  14. 14.
    Cao ZA, Daniel D, Hanahan D (2002) Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11PubMedCrossRefGoogle Scholar
  15. 15.
    Maine GN, Mule JJ (2002) Making room for T cells. J Clin Invest 110:157–159PubMedCrossRefGoogle Scholar
  16. 16.
    Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99:931–936PubMedCrossRefGoogle Scholar
  17. 17.
    Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185–192PubMedCrossRefGoogle Scholar
  18. 18.
    Hu HM, Poehlein CH, Urba WJ, Fox BA (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62:3914–3919PubMedGoogle Scholar
  19. 19.
    Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu HM (2003) Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33:2123–2132PubMedCrossRefGoogle Scholar
  20. 20.
    Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76:17–27PubMedCrossRefGoogle Scholar
  21. 21.
    Ikawa M, Yamada S, Nakanishi T, Okabe M (1998) ‘Green mice’ and their potential usage in biological research. FEBS Lett 430:83–87PubMedCrossRefGoogle Scholar
  22. 22.
    Geller AI, Freese A (1990) Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. Proc Natl Acad Sci USA 87:1149–1153PubMedCrossRefGoogle Scholar
  23. 23.
    Bowers WJ, Olschowka JA, Federoff HJ (2003) Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther 10:941–945PubMedCrossRefGoogle Scholar
  24. 24.
    Dhanji S, Teh SJ, Oble D, Priatel JJ, Teh HS (2004) Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors. Blood 104:2116–2123PubMedCrossRefGoogle Scholar
  25. 25.
    Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN (2006) A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107:935–944PubMedCrossRefGoogle Scholar
  26. 26.
    Strbo N, Oizumi S, Sotosek-Tokmadzic V, Podack ER (2003) Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity 18:381–390PubMedCrossRefGoogle Scholar
  27. 27.
    el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29:3295–3301PubMedCrossRefGoogle Scholar
  28. 28.
    Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, Planelles V, Rosenblatt JD (1999) Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93:643–654PubMedGoogle Scholar
  29. 29.
    Tolba KA, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ, Rosenblatt JD (2002) Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 62:6545–6551PubMedGoogle Scholar
  30. 30.
    Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW (2004) The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 173:1738–1743PubMedGoogle Scholar
  31. 31.
    Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ (2001) Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 166:1097–1105PubMedGoogle Scholar
  32. 32.
    Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141–1151PubMedCrossRefGoogle Scholar
  33. 33.
    Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF (1999) Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162:3256–3262PubMedGoogle Scholar
  34. 34.
    Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174:4465–4469PubMedGoogle Scholar
  35. 35.
    CpG 7909: PF 3512676, PF-3512676. Drugs 2006 R D, 7:312–316Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Hovav Nechushtan
    • 1
    • 2
  • Dien Pham
    • 1
  • Yu Zhang
    • 1
  • Daniel Morgensztern
    • 1
  • Kyung H. Yi
    • 1
  • Seung-Uon Shin
    • 1
  • Howard J. Federoff
    • 3
  • William J. Bowers
    • 3
  • Khaled A. Tolba
    • 1
  • Joseph D. Rosenblatt
    • 1
  1. 1.Division of Hematology–Oncology, Departments of Medicine and Microbiology and Immunology, Miller School of Medicine at the University of MiamiSylvester Comprehensive Cancer CenterMiamiUSA
  2. 2.Department of Medical OncologyHebrew University Hadassah School of MedicineJerusalemIsrael
  3. 3.Departments of Neurology, Microbiology and Immunology, Center for Aging and Developmental BiologyUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations